These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24340644)

  • 1. [Nanoparticles as drug delivery system for antituberculous drugs].
    Sanzhakov MA; Ipatova OM; Torkhovskaia TI; Prozorovskiĭ VN; Tikhonova EG; Druzhilovskaia OS; Medvedeva NV
    Vestn Ross Akad Med Nauk; 2013; (8):37-44. PubMed ID: 24340644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respirable nanocarriers as a promising strategy for antitubercular drug delivery.
    Mehanna MM; Mohyeldin SM; Elgindy NA
    J Control Release; 2014 Aug; 187():183-97. PubMed ID: 24878180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
    Banyal S; Malik P; Tuli HS; Mukherjee TK
    Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.
    Gelperina S; Kisich K; Iseman MD; Heifets L
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1487-90. PubMed ID: 16151040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanostructured drug delivery for better management of tuberculosis.
    Kaur IP; Singh H
    J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomes as drug delivery systems for the treatment of TB.
    Pinheiro M; Lúcio M; Lima JL; Reis S
    Nanomedicine (Lond); 2011 Oct; 6(8):1413-28. PubMed ID: 22026379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug delivery system on the base of phospholipid nanoparticles for rifampicin].
    Sanzhakov MA; Prozorovskiĭ VN; Ipatova OM; Tikhonova EG; Medvedeva NV; Tarkhovskaia TI
    Biomed Khim; 2013; 59(5):585-90. PubMed ID: 24479349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
    Sosnik A; Carcaboso AM; Glisoni RJ; Moretton MA; Chiappetta DA
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):547-59. PubMed ID: 19914315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology based drug delivery system(s) for the management of tuberculosis.
    Pandey R; Khuller GK
    Indian J Exp Biol; 2006 May; 44(5):357-66. PubMed ID: 16708887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-carriers for the Treatment of Tuberculosis.
    Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2006 Jun; 44(6):459-67. PubMed ID: 16784116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary drug delivery systems for tuberculosis treatment.
    Pham DD; Fattal E; Tsapis N
    Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
    Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
    Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis.
    Kaur M; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(1):49-88. PubMed ID: 24579767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.